InnoCan Pharma Corporation
INNPF
$4.95
-$0.03-0.60%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -9.60% | -6.58% | 18.20% | 61.49% | 115.55% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.60% | -6.58% | 18.20% | 61.49% | 115.55% |
| Cost of Revenue | -17.51% | 8.84% | 36.66% | 40.31% | 93.68% |
| Gross Profit | -8.61% | -8.27% | 16.15% | 64.36% | 118.61% |
| SG&A Expenses | -6.30% | -5.83% | 5.12% | 36.28% | 85.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.18% | -6.22% | 4.94% | 32.72% | 75.75% |
| Operating Income | -0.64% | -2.45% | 111.44% | 112.11% | 67.20% |
| Income Before Tax | -90.75% | -550.60% | 128.66% | 153.96% | 122.79% |
| Income Tax Expenses | -63.93% | -45.01% | 1.19% | 169.87% | 451.87% |
| Earnings from Continuing Operations | -30.15% | -122.18% | 90.13% | 121.53% | 93.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 50.19% | 37.92% | -4.02% | -122.65% | -247.02% |
| Net Income | 38.71% | -24.20% | 63.69% | 87.51% | 60.98% |
| EBIT | -0.64% | -2.45% | 111.44% | 112.11% | 67.20% |
| EBITDA | -0.08% | -2.62% | 112.83% | 113.17% | 67.84% |
| EPS Basic | 43.46% | -14.39% | 66.98% | 88.72% | 62.94% |
| Normalized Basic EPS | 11.14% | -18.82% | 71.42% | 93.03% | 68.05% |
| EPS Diluted | 43.46% | -14.39% | 66.98% | 88.72% | 62.94% |
| Normalized Diluted EPS | 11.14% | -18.82% | 71.42% | 93.03% | 68.05% |
| Average Basic Shares Outstanding | 4.21% | 5.71% | 7.01% | 8.85% | 8.87% |
| Average Diluted Shares Outstanding | 4.21% | 5.71% | 7.01% | 8.85% | 8.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |